Related Experiment Videos
Emerging drug treatments for solid tumours
J H Schellens1, L C Pronk, J Verweij
1Department of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek, Rotterdam, The Netherlands.
Abstract:
A number of novel anticancer agents have emerged during the past few decades, which show high activity in preclinical tumour models and promising activity in early trials in patients with solid tumours. Most of the agents have novel and unique mechanisms of action, and show activity against a variety of malignancies, including tumours which are notoriously resistant to systemic treatment. Recently, our understanding of the molecular basis of cancer has increased considerably. This is reflected in the development of agents that are directed at well defined molecular targets, such as the mitotic tubulin/microtubuli system (taxoids), nuclear enzymes (topoisomerase I inhibitors) and cell signal transduction pathways (protein kinase C inhibitors). In addition, significant advances have been made in our understanding of mechanisms of toxicity, especially of cisplatin. This has resulted in the development of agents modulating cisplatin toxicity, among which amifostine (WR-2721) is one of the most promising. The outlined emerging drug therapies with novel anticancer agents and treatment modalities will, it is hoped, result in increased response rates of advanced tumours, longer disease-free and total survival and better palliative care.
Insights
Novel anticancer agents targeting specific molecular pathways show promise against resistant solid tumors. These new therapies aim to improve treatment response, survival rates, and palliative care for advanced cancer patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Recent decades have seen the emergence of novel anticancer agents with significant preclinical and early clinical activity.
- These agents often possess unique mechanisms of action, demonstrating efficacy against various malignancies, including drug-resistant tumors.
Purpose of the Study:
- To review emerging drug therapies and treatment modalities in oncology.
- To highlight novel anticancer agents targeting specific molecular pathways and discuss advances in understanding and modulating drug toxicity.
Main Methods:
- Review of novel anticancer agents and their mechanisms of action.
- Discussion of molecular targets such as the mitotic tubulin/microtubuli system, nuclear enzymes, and cell signal transduction pathways.
- Examination of advances in understanding and managing drug toxicity, exemplified by cisplatin and amifostine (WR-2721).
Main Results:
- Novel agents show high activity in preclinical models and promising results in early patient trials for solid tumors.
- Development of targeted therapies based on increased understanding of cancer's molecular basis.
- Progress in understanding and modulating drug toxicity, leading to agents like amifostine.
Conclusions:
- Emerging drug therapies and novel anticancer agents offer hope for improved outcomes in advanced cancer.
- These advancements are expected to increase response rates, prolong disease-free and overall survival, and enhance palliative care.